Should we still consider colchicine in treating patients with COVID-19?

Putra, O N; Sofia, S; Widad, A; Oktaviani, C R

Putra, O N; Sofia, S; Widad, A; Oktaviani, C R.

Putra ON; Department of Clinical Pharmacy, Study Program of Pharmacy, Hang Tuah University, Surabaya, East Java, Indonesia. oki.nugraha@hangtuah.ac.id.

Eur Rev Med Pharmacol Sci ; 26(4): 1073-1074, 2022 02.

Article in English | MEDLINE | ID: covidwho-1732620

Subject(s)

COVID-19 Drug Treatment; Colchicine/therapeutic use; Colchicine/adverse effects; Humans; Indonesia; Treatment Outcome

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Colchicine / COVID-19 Drug Treatment Type of study: Prognostic study Limits: Humans Country/Region as subject: Asia Language: English Journal: Eur Rev Med Pharmacol Sci Journal subject: Pharmacology / Toxicology Year: 2022 Document Type: Article Affiliation country: Eurrev_202202_28095

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google